Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate

ProstaLundPress release2024-10-04 13:00

A research team from Italy recently published a report in the Central European Journal of Urology on two patients undergoing transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® (registered trademark of ProstaLund AB) before a holmium laser enucleation of the prostate (HoLEP)1. The patients also received moderate sedation/analgesia during the procedure.

General or spinal anaesthesia are the most common anaesthetic modalities used during HoLEP, depending on the surgeon's and anaesthesiologist's preference, patient characteristics, comorbidity, and patient choice. However, general anaesthesia can impact postoperative recovery and expose patients to anaesthesia-related complications. To further reduce the invasiveness of HoLEP, the research team evaluate the feasibility, safety, and advantages of the use of TUIA via the Schelin Catheter®.

The authors conclude that preliminary results demonstrate that TUIA via the Schelin Catheter® was safe and feasible, providing effective operative and postoperative pain control while shortening hospitalization and treatment time.

Reference:
1. Romagnoli D et al. Holmium laser enucleation of the prostate with transurethral intraprostatic anaesthesia using Schelin catheter: a preliminary communication. Cent European J Urol. 2024;77: 273-277.

For further information, please contact:


Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About Schelin Catheter®


The Schelin Catheter® is a transurethral catheter with a retractable needle enabling sterile intraprostatic injections of pharmaceuticals during diagnostic or treatment procedures for the prostate. The Schelin Catheter® is primarily used for transurethral intraprostatic anaesthesia (TUIA) during minimal invasive treatments for benign prostatic enlargement offering effective pain control, replacing the need for general or spinal anaesthesia. For more information visit, www.schelincatheter.com.

About ProstaLund


ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,600 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments


First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate